Does Insurance Cover Home Phototherapy for Chronic Skin Conditions Like Vitiligo, Psoriasis, Eczema, & CTCL? 2026 Guide to Access, Coverage, and Cost

April 21, 2026

By Padma Sundar
Chief Commercial Officer, Phothera

For millions of Americans living with psoriasis, vitiligo, atopic dermatitis (eczema), and cutaneous T-cell lymphoma (CTCL), access to narrowband ultraviolet B (UVB) (NB-UVB) phototherapy has long been constrained by a frustrating gap between clinical evidence and insurance coverage. That gap is narrowing faster than at any point in the history of home phototherapy.

Two landmark policy decisions from national insurers Cigna^® Healthcare and Elevance Health/Anthem^® have further expanded coverage for home phototherapy, which is already broadly covered by insurance. Here is what has changed, what it means for patients and providers, and how Phothera Cares handles prior authorization, claims, and appeals to support broader patient access.

The Coverage Landscape Has Shifted

Cigna Removed Prior Restrictions on Home Phototherapy: 19.2 Million Lives Affected

Effective July 15, 2025, Cigna updated its coverage policy to remove prior restrictions on home phototherapy. The change applies to Cigna’s 19.2 million covered members nationwide and opens access for eligible patients with psoriasis, eczema, and vitiligo to receive clinically proven NBUVB treatment at home without the coverage limitations that previously blocked or delayed access.

This was not a minor administrative revision. Cigna’s prior policy imposed conditions that created friction at the point of prescribing, requirements that, in practice, pushed patients toward in-office treatment or biologics before phototherapy as a first line option.

Elevance Health/Anthem Removed Prior Restrictions on Home Phototherapy: 47.5 Million Lives Affected

Shortly after Cigna, Elevance Health/Anthem implemented a similar policy change, which covers 47.5 million members. With both major insurance carriers aligned on home phototherapy coverage without restrictions, more than 66 million insured Americans have expanded access to FDA-cleared NB-UVB treatment.

To put that number in context: an estimated 8 million Americans live with psoriasis, over 16 million with atopic dermatitis, and approximately 3 million with vitiligo.¹⁻³ A significant portion of those patients are covered by Cigna or Elevance, and as of mid-2025, their path to treatment with home phototherapy is now made much easier by the insurance driven policy changes.

Commercial Insurance: Broadly Covered

Beyond Cigna and Elevance, Phothera devices are broadly covered by insurance for vitiligo, psoriasis, atopic dermatitis (eczema), and CTCL. Coverage criteria and prior authorization requirements vary by plan, but the clinical foundation supporting medical necessity determinations is strong, anchored by the American Academy of Dermatology (AAD) treatment guidelines and landmark peer-reviewed data including the 783-patient LITE Study, published in JAMA Dermatology in 2024.4 Home phototherapy is also covered by a number of leading health systems across the country, including the VA, Kaiser Permanente, UPMC, and Mayo Clinic, reflecting its established efficacy, safety profile, and favorable health economic value proposition.

Why the Clinical Case for Home Phototherapy Is Compelling

The coverage trend tracks the evidence. The LITE Study, the largest randomized clinical trial of its kind, found that home phototherapy achieves 3x higher patient adherence compared to in-office treatment across all skin types: 51% vs. 16% (p<0.001).⁴^,⁵ That is not a marginal difference. It is the kind of gap that changes long-term outcomes.

For vitiligo specifically, NB-UVB is first-line per AAD guidelines, with a 74% patient response rate at 6 months and a 36% marked response (greater than 75% repigmentation) at 12 months.⁵^,⁶ When combined with topical calcineurin inhibitors, phototherapy is 3x more effective than topical monotherapy alone, a finding drawn from a meta-analysis of 46 studies covering nearly 1,500 patients.⁵

When clinical evidence demonstrates clear efficacy, strong substantiation, and favorable performance versus other treatment modalities, payer policy tends to align with the strength of the data, leading to expanded coverage.

What Phothera Cares Does

Having coverage in place does not always mean patients can easily access treatment. In 2025, Phothera made it a core mission to ensure that cost would never be a barrier to patient access. That commitment is the foundation of Phothera Cares program.

Phothera Cares handles prior authorization, insurance claims, and appeals for coverage denials to support broader patient access. Eligible insured patients who qualify for financial assistance may have a $0 patient cost.* Phothera devices are broadly covered by insurance for vitiligo, psoriasis, atopic dermatitis, and CTCL. The device ships free, directly to the patient’s home.

For practices prescribing through EMA^® (Electronic Medical Assistant by Modernizing Medicine), the preferred submission method, required fields are captured automatically at the point of order. Once the prescription is submitted, Phothera manages insurance verification, prior authorization, claims submission, and appeals. The practice will prescribe the home phototherapy device. Phothera will handles the rest of the process, including confirming any incomplete information directly with the patient. This removes the burden on the practice staff to manage a separate workflow.

What Phothera Cares Covers

Prior authorization submission and follow-up
Claims filing and management
Appeals for denied claims
Patient billing support. Phothera does not send patients to collections
Free shipping directly to the patient’s home

Phothera devices are broadly covered by insurance for vitiligo, psoriasis, atopic dermatitis, and CTCL.

What This Means for Dermatology Practices

The practical implication of expanded coverage is that the friction around prescribing home phototherapy is lower than it has been at any point in recent history. With broad coverage across major payors including United, Cigna, and Elevance having removed prior restrictions, the conversation between a dermatologist and a patient about home phototherapy can focus on clinical fit rather than access.

Phothera’s FDA-cleared devices are built for real-world use: pediatric, adult, geriatric, first-line, combination therapy, and safe for use during pregnancy. Phothera offers devices for every patient need, from handheld units designed for targeted spot treatment, to panel units for hands and feet, to full-body systems. Larger panel and full-body units include Guided Mode, an on-device application that delivers AAD guideline-based protocols with built-in safety guardrails, step by step, session by session. Guided Mode automatically tracks and adjusts patient dosing, maintaining safe physician-directed treatment at home.

For practices already using EMA, onboarding takes approximately 10 minutes with a Phothera account manager. Training resources are included.

The Bottom Line

The insurance landscape for home phototherapy in 2026 is the most favorable it has ever been. Phothera devices are broadly covered by insurance for vitiligo, psoriasis, atopic dermatitis, and CTCL, and two of the largest commercial carriers in the country have removed prior restrictions altogether. And Phothera Cares handles prior authorization, claims, and appeals to support broader patient access. Eligible insured patients pay $0.* The practice prescribes. Phothera handles the rest.

For patients who have been waiting, or whose physicians have hesitated to prescribe because of coverage uncertainty, now is the time to revisit the conversation. Explore our website to learn about our product line.

Phothera devices are FDA-cleared for vitiligo, psoriasis, atopic dermatitis, CTCL, and other photoresponsive skin diseases. Phothera brings over 80 years of combined phototherapy experience to every prescription.

Phothera. Embrace Life With Confidence.

References

Gondo GC, et al. Psoriasis Health Indicator Report, https://www.psoriasis.org/health-indicator-report. Accessed: 15, April 2026.
Chiesa Fuxench ZC, et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol. 2019;139(3):583-590.
Napatalung L, et al. JAMA Dermatology. 2022. doi:10.1001/jamadermatol.2021.4724.
Gelfand JM, Armstrong AW, Lim HW, et al. JAMA Dermatol. 2024; doi:10.1001/jamadermatol.2024.3897.
Lee JH, et al. JAMA Dermatol. 2019;155(8):929-938.
Bae JM, et al. JAMA Dermatol. 2017;153(7):666-674.
Silpa-Archa N, et al. J Dermatolog Treat. 2019;30(7):691-696.

*$0 patient cost applies to eligible insured patients. Not all patients will qualify.